(Sharecast News) - Shield Therapeutics reported a strong third-quarter performance for its iron deficiency treatment Accrufer in the US on Tuesday, achieving net revenue of $7.2m.
The AIM-traded firm said that was supported by a 20% increase in prescriptions from the second quarter, and an 86% rise compared to the third...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE